You are here: Industry Insights > tumor

News List

Drug Research and Development of Targeting STAT3: Next Outlet for Antitumor Drugs PharmaSources/Yuntian
August 11, 2021
STAT3 is a major member of signal transduction and activating transcription factor (STAT). According to some studies, it is verified that STAT3 can regulate the growth cycle and immune response of cells.
A Glimpse of the Oncology Drug Treatment Market in China PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
With Zero Five-Year Recurrences, the Emerging Tumor Vaccine Brings Hope of Cure PharmaSources/Wang Hong
January 21, 2021
Undoubtedly, vaccines are one of the most significant milestone inventions in mankind’s fight against diseases, and they have also played an essential role in the treatment of cancer.
The tumor disappears after infection with coronavirus! Looking at the “killing cancer with the virus” concept in the oncology field PharmaSources/Wang Hong
January 21, 2021
The world is full of wonders. According to an article published by a British doctor in the British Journal of Haematology two days ago, a malignant lymphoma patient’s tumor almost disappeared after infection with coronavirus!
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting PharmaSources
April 18, 2023
April 18, 2023，Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China PharmaSources
March 10, 2023
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 inhibitor ICP-248 in China.
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers drugs.com
February 09, 2022
An experimental therapy that harnesses the body's tumor-fighting immune cells...
Pre-Op Treatment May Be Advance Against Deadly Liver Cancers drugs.com
January 28, 2022
When delivering a liver cancer diagnosis, Dr. Thomas Marron pulls no punches: "Liver cancer is one of the deadliest cancers," he tells patients.
FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate contractpharma
December 17, 2021
Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.
NEUVOGEN Appoints Mark W. Frohlich to its Board of Directors and Scientific Advisory Board firstwordpharma
August 24, 2021
NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Mark W. Frohlich, MD to its Board of Directors and Scientific Advisory Board ("SAB") effective August 23, 2021.

Previous page 1 2 3 4 5 6 7 8 Next page